Interactions between genotype and phenotype in bleeding and thrombosis

Haematologica

Volumn 93, Issue 5, 2008, Pages 649-652

  Franchini, Massimo ^a   Mannucci, Pier Mannuccio ^b  

^a City Hospital of Verona   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROCOAGULANT; PROTHROMBIN;

BLEEDING; CLINICAL FEATURE; DNA POLYMORPHISM; EDITORIAL; GENE INTERACTION; GENE MUTATION; GENETIC DISORDER; HEMOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; PHENOTYPE; THROMBOSIS; VENOUS THROMBOEMBOLISM; VITAMIN INTAKE; VON WILLEBRAND DISEASE;

BLOOD COAGULATION; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMORRHAGE; HEMOSTASIS; HETEROZYGOTE; HUMANS; MALE; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; RISK; THROMBOSIS;

EID: 43449121884     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12356     Document Type: Editorial

References (19)

1. Zöller B, Garcia de Frutos P, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica 1999;84:59-70.
2. Buller HR, Agnelli G, Hull RD, Hyers TM, Prius MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 [3 Suppl]:401S-28S.
3. van't Veer C, Golden NJ, Kalafatis M, Simioni P, Bertina RM, Mann KG. An in vitro analysis of the combination of hemophilia A and factor V Leiden. Blood 1997;90:3067-72.
4. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van der Berg HM. Do prothrombotic factors influence clinical phenotype of severe hemophilia? A review of the literature. Thromb Haemost 2004;92:305-10.
5. Minano A, Ordonez A, Espana Gonzales-Porras JR, Lecumbezzi R, Potecuberd J, et al. ABO blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica 2008;93:729-734.
6. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
7. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995;346:1593-6.
8. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19:700-3.
9. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002;116:851-4.
10. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115:415-20.
11. Gemmati D, Previati M, Serino ML, Moratelli S, Guerra S, Capitani S, et al. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. Arterioscler Thromb Vasc Biol 1999;19:1761-7.
12. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst (e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.
13. De Stefano V, Zappacosta B, Persichilli S, Rossi E, Casorelli I, Paciaroni K, et al. Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol 1999;106:564-8.
14. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 1999;93:1-8.
15. Keijzer MBA, Borm GF, Blom HJ, Bos GM, Rosendaal FR, den Heijer M. No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case-only study. Thromb Haemost 2007;97:32-7.
16. Corral J, Iniesta JA, Gonzalez-Conejero R, Villalon M, Vicente V. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood 2001;97:2979-82.
17. Lindqvist PG, Svensson PJ, Dahlback B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - a possible evolutionary selection mechanism. Thromb Haemost 1998;79:69-73.
18. Lindqvist PG, Zoller B, Dahlback B. Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden - an evolutionary advantage? Thromb Haemost 2001;86:1122-3.
19. Clark P, Walker ID, Gavon L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO (H) blood groups on hemorrhagic and thrombotic pregnancy outcome. Br J Haematol 2008;140:236-40.